Variable surface area stent

• US 6,764,505 B1
• Filed: 04/12/2001
• Issued: 07/20/2004
• Est. Priority Date: 04/12/2001
• Status: Expired due to Term

• Current Assignee: Advanced Cardiovascular Systems Incorporated (Abbott Laboratories)
• Original Assignee: Advanced Cardiovascular Systems Incorporated (Abbott Laboratories)
• Inventors: Cahill, Brian P., Hossainy, Syed, Tang, Fuh-Wei
• Primary Examiner(s): Isabella, David J.
• Assistant Examiner(s): Sweet, Thomas
• Application Number:
  US09/834,012
• Time in Patent Office: 1,195 Days
• Field of Search: 623/1.15, 623/1.42, 623/1.39, 427/2.25
• US Class Current: 623/1.15
• CPC Class Codes: A61F 2/91 made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
• CPC Class Codes: A61F 2/915 with bands having a meander structure, adjacent bands being connected to each other
• CPC Class Codes: A61F 2002/91533 characterised by the phase between adjacent bands
• CPC Class Codes: A61F 2002/91575 connected peak to trough
• CPC Class Codes: A61F 2210/0095 radioactive
• CPC Class Codes: A61F 2230/0013 Horseshoe-shaped, e.g. crescent-shaped, C-shaped, U-shaped
• CPC Class Codes: A61F 2250/0025 differing in roughness
• CPC Class Codes: A61F 2250/0067 Means for introducing or releasing pharmaceutical products into the body
• CPC Class Codes: A61F 2250/0068 the pharmaceutical product being in a reservoir

Abstract

A stent of variable surface area as determined by stent struts. The stent can have a variable surface area per unit length which accommodates a therapeutic agent. A patterned distribution of therapeutic agent can be provided throughout the stent. The stent can have an increased level of therapeutic agent near an end of the stent. A decreased level of therapeutic agent can be provided near an end of one embodiment of a stent. Indentations can be provided at the surface of the stent with therapeutic agent disposed therein. The stent can be cut with struts of variable thickness to provide the variable stent surface area.

Claims

1. A drug eluting stent, comprising:

a body having a first end and a second end and a middle segment between said first and second ends;

a variable stent surface area per unit length of said body, wherein said first and second ends have a lesser surface area than said middle segment; and

a drug deposited on said stent so that said first and second ends have a lesser amount of said drug than said middle segment.

2. The stent of claim 1, wherein said body comprises struts having a roughened portion with a roughness factor above 1 to provide said variable stent surface area.

3. The stent of claim 2, wherein said roughened portion is provided by a method of etching a portion of said struts.

4. The stent of claim 2, wherein said struts comprise:

a loading surface at an exterior portion of said stent to accommodate said drug; and

an interior portion of said stent void of said roughened portion.

5. The stent of claim 1, wherein said body comprises struts having a thickened portion to provide said variable stent surface area.

6. The stent of claim 5, wherein said thickened portion is provided by an increased radius portion.

7. The stent of claim 5, wherein said thickened portion is provided by cutting a stent pattern from a tube, said stent pattern indicating said thickened portion.

8. The stent of claim 7, wherein said cutting is performed by an automated laser method.

9. The stent of claim 1, wherein said body comprises increased size indentations having a depth beyond about 80 micrometers to provide said variable stent surface area.

10. The stent of claim 1, wherein said drug is deposited in a polymeric coating.

11. The stent of claim 1, wherein said drug is an anti-coagulant.

12. The stent of claim 1, wherein said drug is encased in an anti-coagulant barrier.

13. A drug eluting stent, comprising:

a body having a first end and a second end and a middle segment between said first and second ends;

a variable stent surface area per unit length of said body, wherein said first and second ends have a greater surface area than said middle segment; and

a drug deposited on said stent so that said first and second ends have a greater amount of said drug than said middle segment.

14. The stent of claim 13, wherein said body comprises struts having a roughened portion with a roughness factor above 1 to provide said variable stent surface area.

15. The stent of claim 14, wherein said roughened portion is provided by a method of etching a portion of said struts.

16. The stent of claim 13, wherein said struts comprise:

a loading surface at an exterior portion of said stent to accommodate said drug; and

an interior portion of said stent void of said roughened portion.

17. The stent of claim 13, wherein said body comprises struts having a thickened portion to provide said variable stent surface area.

18. The stent of claim 17, wherein said thickened portion is provided by an increased radius portion.

19. The stent of claim 17, wherein said thickened portion is provided by cutting a stent pattern from a tube, said stent pattern indicating said thickened portion.

20. The stent of claim 19, wherein said cutting is performed by an automated laser method.

21. The stent of claim 13, wherein said body comprises increased size indentations having a depth beyond about 80 micrometers to provide said variable stent surface area.

22. The stent of claim 13, wherein said drug is deposited in a polymeric coating.

23. The stent of claim 13, wherein said drug is an anti-coagulant.

24. The stent of claim 13, wherein said drug is encased in an anti-coagulant barrier.

25. A drug eluting stent, comprising:

a stent body having a first end, an opposing second end, and a middle segment positioned between said first and second ends; and

a drug disposed on said stent, wherein the concentration or amount of said drug is higher at said first or second end as compared to said middle segment of said body positioned between said first and second ends.

26. The stent of claim 25, wherein said stent is used to deliver said drug for the treatment of edge-restenosis.

27. The stent of claim 25, wherein said drug is released from a polymer.

28. The stent of claim 25, wherein the concentration or amount of drug is higher at both said first and second ends as compared to said middle segment.

29. The stent of claim 25, wherein said body is made from a plurality of interconnected struts such that the surface area of at least some of the individual struts forming said first or second end is greater than the surface area of said struts forming said middle segment of said body so that a higher concentration or amount of said drug can be carried by said having a greater surface area.